|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Herein, we successfully synthesized a sequential targeting nanoplatform (IR825@Bev-PLGA-PFP NPs) with theranostic function, which specifically binds to VEGF on the tumor cell surface and further cascades into mitochondria to achieve effective accumulation of NPs in the tumor regions.
|
31778831 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mechanistically, ectopic overexpression of miR-126-3p significantly inhibited thyroid cancer cell proliferation, in vitro (p<0.01) and in vivo (p<0.01), colony formation (p<0.01), tumor spheroid formation (p<0.05), cellular migration (p<0.05), VEGF secretion and endothelial tube formation, and lung metastasis in vivo.
|
26244545 |
2015 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present report is the original state of art technology to selectively target dual drug (DTX and GEM) loaded BSA NPs via exploring tumor targeting potential of AA, having high affinity towards VEGF receptors (angiogenesis marker) overexpressed in tumor.
|
29649635 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, redox active selenium compounds do not kill or inactivate immune cells at doses required for anti-cancer treatment, and we demonstrate that MSA enhances T cell-mediated tumor cell killing via PDL1 and VEGF inhibition.
|
30324091 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We observed that CK19, MUC1, HER1-HER3, uPA, and VEGF had a significantly higher expression in cervical tumors than in the negative nodes, whereas VEGF-C expression level was higher in the negative nodes than in the tumors.
|
18629779 |
2008 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment.
|
30698737 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Surprisingly, complete tumor inhibition occurs in the absence of VEGF in EGFR mutant mice, demonstrating that VEGFR and EGFR synergize in neoplastic cells to promote tumor growth.
|
20141840 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The growth inhibitory effect of combination therapy was similar to that of the clinical maximum dose of cisplatin; mechanistically, this appeared to predominantly occur via drug-induced cytostatic growth inhibition as well as diminished vascular endothelial growth factor secretion in the tumor models.
|
24442130 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased expression of vascular endothelial growth factor, an angiogenesis factor, and decreased expression of thrombospondin-1, an angiogenesis inhibitor, were also observed in ML.delta betaRII tumors.
|
10383147 |
1999 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<sup>99m</sup>Tc labeled <sub>D</sub>(LPR): A novel retro-inverso peptide for VEGF receptor-1 targeted tumor imaging.
|
29885559 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF occurs also in canine tumors in similar relative quantities as in human malignancies.
|
10661874 |
1999 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of VEGF correlated positively to tumor microvessel density and to VEGFR-2 expression at the protein (P<0.05) and mRNA (P<0.05) levels.
|
21041381 |
2011 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Since melatonin has anti-angiogenic effects in tumor cell lines, the aim of the present study was to study melatonin modulation of the pro-angiogenic effects of VEGF in neuroblastoma cells (SH-SY5Y).
|
28259965 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent studies demonstrated a key role for VEGF in tumor neovascularization, which is a prerequisite for tumor proliferation and metastasis.
|
8589021 |
1995 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The extent of angiogenesis and/or vascular endothelial growth factor (VEGF) expression in neuroblastoma tumors correlates with metastases, N-myc amplification, and poor clinical outcome.
|
15930297 |
2005 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, NPTN over-expression in a breast cancer cell line resulted in a significant increase in tumor growth and angiogenesis in vivo which was related to increased VEGF production in the transfected cells.
|
18568347 |
2009 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development and progression of solid tumours.
|
22315135 |
2012 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.
|
22498007 |
2012 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Other exploratory correlations included epidermal growth factor receptor to perineural invasion (P = .05), and certain vascular endothelial growth factor receptors and ligands to mass effect (P = .03) and increased (P = .01) or decreased (P = .02) primary tumor size.
|
23764725 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this mini-review, we explore the role of VEGF inhibitors in the tumor microenvironment with focus on the immune system, discussing around the functional contribution of both bevacizumab's Fab and Fc domains to the therapeutic results and the combination of bevacizumab therapy with other immune-stimulatory settings, including adjuvant-based vaccine approaches.
|
31156623 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression.
|
23226093 |
2012 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This also occurred in VEGF(189) tumors, but there, vasodilation was less pronounced.
|
14500375 |
2003 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of KDR (one of the VEGF receptors) mRNA in tumor exceeded that in normal tissues.
|
11679938 |
2001 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It is reported that the autocrine loop of the vascular endothelial growth factor (VEGF) is crucial for the survival and proliferation of non-small cell lung cancer (NSCLC) tumors.
|
23459872 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment.
|
31403867 |
2019 |